$140.09
+6.43
(+4.81%)▲
Insights on Neurocrine Biosciences Inc.
Revenue is up for the last 8 quarters, 310.6M → 515.2M (in $), with an average increase of 6.8% per quarter
Netprofit is up for the last 2 quarters, 83.1M → 147.7M (in $), with an average increase of 43.7% per quarter
0.56%
Downside
Day's Volatility :3.7%
Upside
3.15%
36.44%
Downside
52 Weeks Volatility :39.99%
Upside
5.58%
Period | Neurocrine Biosciences Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.01% | 1.9% | 0.0% |
6 Months | 28.23% | 10.7% | 0.0% |
1 Year | 35.27% | 4.6% | -1.1% |
3 Years | 41.85% | 14.2% | -22.1% |
Market Capitalization | 13.3B |
Book Value | $22.61 |
Earnings Per Share (EPS) | 2.47 |
PE Ratio | 53.44 |
PEG Ratio | 0.44 |
Wall Street Target Price | 151.96 |
Profit Margin | 13.23% |
Operating Margin TTM | 29.17% |
Return On Assets TTM | 8.78% |
Return On Equity TTM | 12.68% |
Revenue TTM | 1.9B |
Revenue Per Share TTM | 19.32 |
Quarterly Revenue Growth YOY | 25.0% |
Gross Profit TTM | 1.0B |
EBITDA | 416.1M |
Diluted Eps TTM | 2.47 |
Quarterly Earnings Growth YOY | 0.65 |
EPS Estimate Current Year | 4.78 |
EPS Estimate Next Year | 6.4 |
EPS Estimate Current Quarter | 1.14 |
EPS Estimate Next Quarter | 1.06 |
What analysts predicted
Upside of 8.47%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 451.2M | ↑ 179.19% |
Net Income | 21.1M | ↓ 114.81% |
Net Profit Margin | 4.68% | ↑ 92.87% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 788.1M | ↑ 74.65% |
Net Income | 37.0M | ↑ 75.26% |
Net Profit Margin | 4.69% | ↑ 0.01% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 32.71% |
Net Income | 407.3M | ↑ 1000.81% |
Net Profit Margin | 38.94% | ↑ 34.25% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 8.38% |
Net Income | 89.6M | ↓ 78.0% |
Net Profit Margin | 7.9% | ↓ 31.04% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 31.34% |
Net Income | 154.5M | ↑ 72.43% |
Net Profit Margin | 10.38% | ↑ 2.48% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 26.76% |
Net Income | 249.7M | ↑ 61.62% |
Net Profit Margin | 13.23% | ↑ 2.85% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 387.9M | ↑ 2.56% |
Net Income | 68.5M | ↓ 505.33% |
Net Profit Margin | 17.66% | ↑ 22.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 412.0M | ↑ 6.21% |
Net Income | 89.0M | ↑ 29.93% |
Net Profit Margin | 21.6% | ↑ 3.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 420.4M | ↑ 2.04% |
Net Income | -76.6M | ↓ 186.07% |
Net Profit Margin | -18.22% | ↓ 39.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 452.7M | ↑ 7.68% |
Net Income | 95.5M | ↓ 224.67% |
Net Profit Margin | 21.1% | ↑ 39.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 498.8M | ↑ 10.18% |
Net Income | 83.1M | ↓ 12.98% |
Net Profit Margin | 16.66% | ↓ 4.44% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 515.2M | ↑ 3.29% |
Net Income | 147.7M | ↑ 77.74% |
Net Profit Margin | 28.67% | ↑ 12.01% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 993.2M | ↑ 21.47% |
Total Liabilities | 512.4M | ↑ 15.03% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 31.5% |
Total Liabilities | 669.1M | ↑ 30.59% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 32.83% |
Total Liabilities | 608.5M | ↓ 9.06% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.1B | ↑ 19.47% |
Total Liabilities | 698.5M | ↑ 14.79% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 14.29% |
Total Liabilities | 660.9M | ↓ 5.38% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 3.3B | ↑ 37.27% |
Total Liabilities | 1.0B | ↑ 54.24% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↑ 6.87% |
Total Liabilities | 598.8M | ↑ 2.83% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | ↑ 10.51% |
Total Liabilities | 660.9M | ↑ 10.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.4B | ↓ 0.38% |
Total Liabilities | 675.3M | ↑ 2.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 10.73% |
Total Liabilities | 760.1M | ↑ 12.56% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | ↑ 9.0% |
Total Liabilities | 846.1M | ↑ 11.31% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↑ 14.16% |
Total Liabilities | 1.0B | ↑ 20.48% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 101.4M | ↓ 207.46% |
Investing Cash Flow | -242.9M | ↓ 3.17% |
Financing Cash Flow | 29.5M | ↓ 94.28% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 152.1M | ↑ 50.01% |
Investing Cash Flow | -211.1M | ↓ 13.11% |
Financing Cash Flow | 27.3M | ↓ 7.51% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 228.5M | ↑ 50.28% |
Investing Cash Flow | 4.1M | ↓ 101.94% |
Financing Cash Flow | -157.8M | ↓ 677.75% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 256.5M | ↑ 12.25% |
Investing Cash Flow | -130.2M | ↓ 3275.61% |
Financing Cash Flow | 27.4M | ↓ 117.36% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 339.4M | ↑ 32.32% |
Investing Cash Flow | -177.1M | ↑ 36.02% |
Financing Cash Flow | -234.3M | ↓ 955.11% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 98.8M | ↓ 28.46% |
Investing Cash Flow | -61.3M | ↓ 295.22% |
Financing Cash Flow | 11.4M | ↓ 104.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 143.0M | ↑ 44.74% |
Investing Cash Flow | -115.6M | ↑ 88.58% |
Financing Cash Flow | 24.6M | ↑ 115.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -125.2M | ↓ 187.55% |
Investing Cash Flow | -42.1M | ↓ 63.58% |
Financing Cash Flow | 8.2M | ↓ 66.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 179.6M | ↓ 243.45% |
Investing Cash Flow | -125.9M | ↑ 199.05% |
Financing Cash Flow | 2.9M | ↓ 64.63% |
Sell
Neutral
Buy
Neurocrine Biosciences Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Neurocrine Biosciences Inc. | -0.11% | 28.23% | 35.27% | 41.85% | 77.04% |
Haleon Plc Spon Ads | -0.24% | 1.82% | -5.93% | 13.5% | 13.5% |
Zoetis Inc. | -10.88% | -10.51% | -15.19% | -11.92% | 47.93% |
Viatris Inc. | -3.97% | 24.7% | 21.76% | -16.16% | -30.48% |
Catalent, Inc. | -0.66% | 31.9% | 24.68% | -51.57% | 26.05% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Neurocrine Biosciences Inc. | 53.44 | 53.44 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 29.86 | 29.86 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 28.76 | 28.76 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 225.0 | 225.0 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Neurocrine Biosciences Inc. | Buy | $13.3B | 77.04% | 53.44 | 13.23% |
Haleon Plc Spon Ads | Buy | $38.2B | 13.5% | 29.86 | 9.28% |
Zoetis Inc. | Buy | $66.5B | 47.93% | 28.76 | 27.43% |
Viatris Inc. | Hold | $13.4B | -30.48% | 225.0 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 26.05% | 211.02 | -31.77% |
BlackRock Inc
Vanguard Group Inc
State Street Corporation
Point72 Asset Management, L.P.
Bellevue Group AG
Morgan Stanley - Brokerage Accounts
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Organization | Neurocrine Biosciences Inc. |
Employees | 1400 |
CEO | Dr. Kevin C. Gorman Ph.D. |
Industry | Health Technology |